Oppenheimer set a $10.00 target price on Mesoblast (NASDAQ:MESO) in a research note issued to investors on Tuesday, TipRanks reports. The firm currently has a buy rating on the stock. Oppenheimer also issued estimates for Mesoblast’s Q1 2020 earnings at ($0.03) EPS, Q2 2020 earnings at ($0.21) EPS, Q3 2020 earnings at ($0.09) EPS, FY2020 earnings at ($0.61) EPS, Q1 2021 earnings at ($0.17) EPS, Q2 2021 earnings at ($0.06) EPS, Q3 2021 earnings at ($0.03) EPS, Q4 2021 earnings at $0.05 EPS, FY2021 earnings at ($0.21) EPS and FY2022 earnings at $0.98 EPS.
MESO has been the subject of several other research reports. HC Wainwright set a $7.00 price target on shares of Mesoblast and gave the company a buy rating in a research note on Friday, August 30th. Chardan Capital set a $6.00 price target on shares of Mesoblast and gave the stock a hold rating in a report on Friday, August 30th. ValuEngine upgraded shares of Mesoblast from a hold rating to a buy rating in a report on Tuesday. Maxim Group reiterated a buy rating and set a $16.00 price objective on shares of Mesoblast in a report on Wednesday, June 12th. Finally, Zacks Investment Research lowered shares of Mesoblast from a buy rating to a hold rating in a research report on Friday, September 6th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $11.25.
Shares of MESO stock traded up $0.58 on Tuesday, reaching $7.33. The stock had a trading volume of 608 shares, compared to its average volume of 43,361. The company has a quick ratio of 1.92, a current ratio of 1.41 and a debt-to-equity ratio of 0.14. The firm’s 50-day moving average is $5.06 and its two-hundred day moving average is $5.09. The firm has a market capitalization of $572.56 million, a price-to-earnings ratio of -7.89 and a beta of 1.77. Mesoblast has a 12 month low of $3.35 and a 12 month high of $8.78.
An institutional investor recently raised its position in Mesoblast stock. Morgan Stanley boosted its position in shares of Mesoblast limited (NASDAQ:MESO) by 284.6% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 147,702 shares of the company’s stock after purchasing an additional 109,295 shares during the quarter. Morgan Stanley owned about 0.16% of Mesoblast worth $784,000 at the end of the most recent reporting period. 2.76% of the stock is currently owned by institutional investors and hedge funds.
Mesoblast Company Profile
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
See Also: Monthly Dividend Stocks
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.